Menin inhibitor ziftomenib (KO-539) synergizes with drugs targeting chromatin regulation or apoptosis and sensitizes acute myeloid leukemia with MLL rearrangement or NPM1 mutation to venetoclax

Haematologica. 2023 Oct 1;108(10):2837-2843. doi: 10.3324/haematol.2022.282160.
No abstract available

Publication types

  • Letter
  • Research Support, N.I.H., Extramural

MeSH terms

  • Apoptosis
  • Chromatin*
  • Humans
  • Leukemia, Myeloid, Acute* / drug therapy
  • Leukemia, Myeloid, Acute* / genetics
  • Mutation
  • Myeloid-Lymphoid Leukemia Protein / genetics
  • Nuclear Proteins / genetics

Substances

  • Chromatin
  • venetoclax
  • Myeloid-Lymphoid Leukemia Protein
  • Nuclear Proteins